The III edition of the congress "Hepatitis B, surgery and liver transplant – Hot Topics in Liver Transplant: new viruses and Hepatitis B”, supported by Kedrion, takes place on 8th and 9th June. The event is being held at the Renaissance Tuscany Il Ciocco Resort and Spa with over 100 Italian transplantologists and hepatologists attending,
Kedrion confirms its commitment to improving access to treatment and protecting the therapeutic standards of people suffering from haemophilia and other haemorrhagic conditions. The company is actually one of the supporters of the initiatives implemented in Rome by FedEmo (Federation of haemophilic patients’ associations) and in Milan by Fondazione Paracelso to celebrate the eighth World
At the yearly PPTA meeting in Brussels, Paolo Marcucci has been elected as new chairman of the Global Board of Directors of the Plasma Protein Therapeutics Association. Paolo Marcucci has served on the PPTA Global Board of Directors since 2008. “It will be a great honor and privilege to serve as the new chairman of
The Regional Health Councillor for Tuscany, Daniela Scaramuccia, visited Kedrion’s plant in Bolognana (Lucca, Italy), with Simona Carli, Regional Director of the National Blood Centre of Tuscany. They were received by Paolo Marcucci, President and CEO of Kedrion, along with the company’s management. It was a particularly important visit for Kedrion, since it was the
Last night, the President of the American Chamber of Commerce in Italy, Vittorio Terzi, gave Paolo Marcucci, President and CEO of Kedrion, the “Transatlantic Award 2011” for the company’s response to the challenges of the international market by investing in quality and technological innovation and for its success in the US market. In 2011, Kedrion
The Biological Safety Centre BioSC will take part in the “Italia degli Innovatori 2011/2012” project, an initiative promoted by the Italian Government to showcase an Italy that can do innovation and our country’s excellent technological achievements. BioSC, a centre specialising in viral validation studies which has been working at the Kedrion’s plant in Bolognana (Lucca
Kedrion, a biopharmaceutical company specialising in the development, manufacture and distribution of plasma-derived products, is one of the major participants in the fifth edition of Forum on Health Risk Management taking place in Arezzo (Italy) until November 26th. In particular, Kedrion took part in the meeting of November 23rd called “Safety of blood-derived products”, chaired
Kedrion has won the institutional Haemophilia Federation India (HFI) award. As part of the celebrations for the 25th anniversary of the foundation of HFI, in New Delhi, India’s Health and Welfare Minister Ambumani Ramadoss gave Kedrion’s Piersergio Martini an award for the company’s long-term support to the mission of increasing the availability of coagulation factors, i.e.
The study Progress in large-scale purification of Factor VIII/von Willebrand factor concentrates using ion-exchange chromatographyhas been published on “Vox Sanguinis” (2008) 95, 298–307, Entirely conducted by Kedrion’s researchers, the study presents the results of the development of a new purification method for a Factor VIII/von Willebrand Factor concentrate. A process scale-up is now being investigated
As part of the XXXVIII National Conference on Transfusion Medicine, the Scientific Committee of SIMTI (Italian Society of Transfusion and Immunohaematologic Medicine) has selected, as the winner for the session “transfusion-transmitted diseases”, the presentation Viral Risk Assessment – Modello Kedrion: applicazione nell’ambito del plasma italiano destinato alla lavorazione industriale (Viral Risk Assessment – Kedrion’s model:
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it. In addition as per local health authority Regulations, some of our products are not approved for sales, marketing or distribution in all countries.